A lot has happened since our last update, so we've got some exciting news to share!

First, Product Development Updates:

• We're conducting industrial design for the commercial version of the Resilient Monitor
• Algorithm development continues with great results to date
• We have an "adherence study" planned to start this April, where patients receiving treatment for opioid use disorder will have the opportunity to wear a prototype Resilient Monitor. This will help determine future adherence to our product.
• We're kicking off conversations with investors this month. Please reach out if you'd like to chat!

Q1 Highlights

1: Resilient Awarded $275k by National Science Foundation

Our National Science Foundation SBIR grant is officially awarded. This means we have $275k from the federal government to continue our research. This grant specifically funds development of our autoinjector mechanism and testing of the stability of our custom formulation of naloxone. There are a lot of reasons to be excited about this:

1. This funding helps us accelerate our drug delivery technology development
2. This adds meaningful time to our runway as a company
3. This endorsement by the National Science Foundation speaks to the importance and credibility of the work that we’re doing

2: Welcoming Al Moghaddam

We’re excited to welcome Al Moghaddam to our team as Chief Commercial Officer. Most Recently, Al served as the global general manager for the Masimo Opioid Halo, reporting to the CEO of the industry leading medical device company. Put simply, Al was responsible for commercializing our predecessor technology.

After leaving Masimo, Al saw the work that we were doing, and was so excited by its potential that he chose to join the team. He brings deep knowledge of the pharmaceutical industry, and opioid and overdose prevention markets. His primary responsibilities will include shaping our go-to-market strategy as well as supporting our regulatory,  product development, and fundraising efforts. Welcome Al!

Al Moghaddam, Resilient's new Chief Commercial Officer

3: Success in Our First Study

We conducted our first feasibility study with a prototype Resilient Monitor in Q3 2023. We studied 30 healthy volunteers across a range of skin tones and BMIs to calibrate the Resilient Monitor's ability to measure heart rate, respiratory rate, and oxygen saturation (these vital signs are then interpreted to detect opioid overdose).

With this data, we've demonstrated ability to measure heart rate and respiratory rate within FDA standards, and informed minor design changes that will improve our oxygen saturation readings.

A participant from our feasibility study walking on a treadmill while wearing the Resilient Monitor and a host of reference medical devices.

‍